. home.aspx

home.aspx
   

EU Approves Two-Drug Pill as First-Line Treatment for HIV

July 03, 2019 / JONATHAN SMITH

The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these medications can have side effects as a result of their interaction with other medicines taken for age-related conditions. ViiV Healthcare’s newly approved drug Dovato is designed to replace the three-drug treatments with just two, reducing these long-term risks in patients beginning HIV treatments.